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PEzetimibe and Simvastatin Reduce
Inflammation, Disease Activity, and Aortic Stiffness and
Improve Endothelial Function in Rheumatoid Arthritis
Kaisa M. Mäki-Petäjä, BSC,* Anthony D. Booth, MD, MRCP,* Frances C. Hall, DPHIL, FRCP,†
Sharon M. L. Wallace, BA, RN,* John Brown, DM, FRCP,‡ Carmel M. McEniery, PHD,*
Ian B. Wilkinson, DM, FRCP*
Cambridge, United Kingdom
Objectives The aim of this study was to investigate the effect of simvastatin and ezetimibe on inflammation, disease activ-
ity, endothelial dysfunction, and arterial stiffness in a cohort of rheumatoid arthritis (RA) patients.
Background Rheumatoid arthritis is a chronic inflammatory condition associated with increased cardiovascular risk. Statins
reduce inflammation and disease activity in RA patients, but whether this is due to pleiotropism or cholesterol
lowering per se is unclear.
Methods Twenty patients received 20 mg simvastatin or 10 mg ezetimibe each for 6 weeks in a randomized double-blind
crossover study. Disease activity, blood pressure, aortic pulse wave velocity (PWV), brachial artery flow-mediated
dilation (FMD), and serum inflammatory markers were measured before and after each treatment.
Results Both ezetimibe and simvastatin significantly reduced total cholesterol (0.62  0.55 mmol/l and 1.28 
0.49 mmol/l, respectively; p  0.001), low-density lipoprotein cholesterol (0.55  0.55 mmol/l and 1.28 
0.49 mmol/l; p  0.0001), and C-reactive protein (5.35  9.25 mg/l and 5.05  6.30 mg/l; p  0.001).
Concomitantly, Disease Activity Score (0.55  1.01 and 0.67  0.91; p  0.002), aortic PWV (0.69 
1.15 m/s and 0.71  0.71 m/s; p  0.001), and FMD (1.37  1.17% and 2.51  2.13%; p  0.001) were
significantly improved by both drugs.
Conclusions This study demonstrates that both ezetimibe and simvastatin reduce disease activity and inflammatory markers
to a similar extent in patients with RA. Therapy is also associated with a concomitant reduction in aortic PWV
and improvement in endothelial function. This suggests that cholesterol lowering per se has anti-inflammatory
effects and improves vascular function in RA. (J Am Coll Cardiol 2007;50:852–8) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.076a
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theumatoid arthritis (RA) is associated with increased
ortality and comorbidity, mostly owing to an excess of
ardiovascular disease (1). This cannot solely be explained
y traditional cardiovascular risk factors (2), which has led
o the suggestion that the chronic systemic inflammation
haracterizing RA may accelerate the atherosclerotic process
ither directly by contributing to plaque formation and
estabilization or indirectly via endothelial dysfunction and
rom the *Clinical Pharmacology Unit and †Department of Clinical Medicine,
ddenbrooke’s Hospital, and ‡Trinity College, University of Cambridge, Cambridge,
nited Kingdom. Kaisa Mäki-Petäjä’s doctoral studies are funded by GlaxoSmith-
line. Drs. Booth and Wilkinson are supported by grants from the British Heart
oundation. Dr. Hall is supported by the British Medical Association’s Doris Hillier
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ardiovascular risk reduction website. The laboratory in which this work was carried
ut is sponsored by the British Heart Foundation.r
Manuscript received February 6, 2007; revised manuscript received April 20, 2007,
ccepted April 22, 2007.ortic stiffening. Aortic stiffening increases wave reflection,
hus increases pulse pressure, leading to elevated left ven-
ricular (LV) load and a possible LV hypertrophy, thus
ncreased cardiovascular risk. Both aortic stiffening and
ndothelial dysfunction predict future cardiovascular risk in
ther patient groups (3,4) and may play a pathophysiologic
ole in atheroma formation. Moreover, we and others have
emonstrated both endothelial dysfunction (5,6) and in-
reased arterial stiffness (7–9) in RA, which can be reversed
y successful anti-inflammatory therapy (9,10).
Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-
oA] reductase inhibitors) are effective in reducing cardiovas-
ular morbidity and mortality in a variety of populations
11,12). In addition to cholesterol reduction, a number of
ther pleiotropic effects have been described with statins
hat may improve outcome independently of cholesterol
eduction (13). One such effect is a reduction in inflamma-
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August 28, 2007:852–8 Cholesterol Reduction and Aortic Stiffness in RAion (14), which is increasingly thought to play an important
ole in the pathogenesis of atherosclerosis. The TARA
Trial of Atorvastatin in Rheumatoid Arthritis) study as-
essed the effect of 6 months’ treatment with atorvastatin in
atients with RA. Statin therapy was associated with a
arked reduction in inflammatory markers (C-reactive
rotein [CRP] and erythrocyte sedimentation rate [ESR])
s well as with a reduction of disease activity (15). That study
id not include any control cholesterol-lowering therapy and it
s therefore unclear whether the observed anti-inflammatory
roperties were a pleiotropic effect of statins or simply due to a
eduction in cholesterol. Moreover, the authors did not assess
he effect of therapy on vascular function.
The aim of the present study was to test the hypothesis
hat cholesterol reduction per se reduces inflammation,
isease activity, and surrogate measures of cardiovascular
isk in patients with RA, by examining the effect of
imvastatin and a nonstatin, ezetimibe, which acts locally by
nhibiting cholesterol absorption from the small intestine, in
randomized double-blind crossover study.
ethods
tudy population. Twenty patients with active RA who
et the 1987 American Rheumatism Association criteria
ere recruited from the rheumatology clinics at Adden-
rooke’s Hospital, Cambridge, United Kingdom. Inclusion
riteria included a Disease Activity Score (DAS)-28 3.5
nd a serum CRP 6 mg/l. Individuals with cardiovascular
isease, untreated hypertension (blood pressure 140/90
m Hg), diabetes, hypercholesterolemia (total cholesterol
6.5 mmol/l), renal disease, and current smokers were
xcluded, because these conditions are associated with
ndothelial dysfunction and arterial stiffening. Patients on
asoactive drugs were also excluded. We also randomly
elected 20 age- and gender-matched control subjects from
ur database to compare the baseline arterial stiffness and
ndothelial function between patients with RA and healthy
ndividuals. Approval was obtained from the Local Research
thics Committee, and written informed consent was
btained from each participant.
emodynamic measurements. All studies were conducted
n a quiet temperature-controlled room. Blood pressure was
ecorded in the brachial artery using a validated oscillomet-
ic technique (HEM-705CP, Omron Corp., Kyoto, Japan).
adial artery waveforms were obtained with a high-fidelity
icromanometer (SPC-301, Millar Instruments, Houston,
exas) from the wrist, and a corresponding central wave-
orm was generated using a validated transfer function
Sphygmocor, AtCor Medical, Sydney, Australia). Aug-
entation index (AIx), a composite measure of systemic
rterial stiffness and wave reflection, mean arterial pressure,
nd heart rate was determined using the integrated software.
ortic (carotid to femoral) pulse wave velocity (PWV) was
easured as previously described (16). wEndothelial function was as-
essed in the brachial artery using
he technique of flow-mediated
ilatation (FMD) (17). Vessel
iameter was measured using
igh-resolution vascular ultra-
ound (Acuson 128XP/10, Sie-
ens, Erlangen, Germany) with
10-MHz linear array trans-
ucer. Brachial artery diameter
as measured continuously for 1
in at baseline and for a further
min after cuff deflation. The
uff was placed below (distal to)
he ultrasound transducer and in-
ated to 200 mm Hg for 5 min.
fter return to baseline, vessel
iameter was again measured continuously for 5 min after
dministration of 25 g sublingual glyceryl trinitrate
GTN). The FMD was defined as the maximum percentage
ncrease in vessel diameter during reactive hyperemia;
TN-mediated dilatation was defined as the maximum
ercentage increase in vessel diameter after sublingual
TN. The FMD recordings were analyzed off line by a
linded operator unfamiliar with the study.
aboratory measurements. Fasting lipid profile, blood
lucose, and high-sensitivity CRP, ESR, and rheumatoid
actor were determined using standard methodology. Oxi-
ized low-density lipoprotein (oxLDL) was measured in
tored serum samples (80°C) by a commercially available
olid-phase two-site enzyme immunoassay (Mercodia,
ppsala, Sweden). The samples were measured in a single
nalytical run.
isease Activity Score. The DAS-28 is a validated com-
osite Disease Activity Score (18). The components of
AS-28 include the number of swollen and tender joints
rom 28 assessed joints, ESR, and patient-assessed visual
nalog score of overall well-being (scaled 0 to 100). The
AS-28 was calculated as previously described (18).
xperimental protocol. The present study was conducted
n a randomized double-blind crossover manner. Following
2-week placebo run-in, patients received 10 mg ezetimibe
r 20 mg simvastatin, in random order, each for 6 weeks,
ith a 6-week washout between drugs (Fig. 1). All hemo-
ynamic measurements were assessed at baseline, following
he end of the placebo run-in, and at the end of each 6-week
eriod (drug 1, washout, and drug 2). Blood was drawn at
ach time point for the measurement of biochemical mark-
rs, and DAS-28 was calculated.
ata analysis. Data were analyzed using SPSS software
version 12, SPSS Inc., Chicago, Illinois). Two-way re-
eated measures analysis of variance was used to investi-
ate the effect of the drugs. Custom hypothesis testing
simple) of within-subject contrasts was performed for the
zetimibe-simvastatin comparison, where treatment order
Abbreviations
and Acronyms
AIx  augmentation index
CRP  C-reactive protein
DAS  Disease Activity
Score
ESR  erythrocyte
sedimentation rate
FMD  flow-mediated
dilatation
GTN  glyceryl trinitrate
oxLDL  oxidized low-
density lipoprotein
PWV  pulse wave velocity
RA  rheumatoid arthritisas entered as a between-subject factor. In post hoc tests,
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Cholesterol Reduction and Aortic Stiffness in RA August 28, 2007:852–8he effect of individual treatments was determined using
aired Student t tests with Bonferroni adjustment for 2
omparisons. For the skewed variables (CRP and ESR)
og-transformed values were used for the analyses. The
arryover effect of the drugs was assessed with paired
tudent t tests between the baseline measurements at
eek 2 (baseline 2) and week 14 (end of washout period).
earson correlations were calculated between absolute
hanges in lipid parameters and anti-inflammatory mark-
rs, hemodynamic measures and disease activity. A prob-
bility of 0.05 was considered to be significant. Data
re given as mean  SD.
esults
total of 20 patients with active rheumatoid arthritis
ompleted the study. The demographic variables and bio-
hemical and hemodynamic characteristics of patients at
ntry are shown in Table 1. There was no difference in the
ipid profile between patients with RA and control subjects
total cholesterol 5.3  0.9 mmol/l vs. 4.9  1.3 mmol/l;
DL 3.1  0.9 mmol/l vs. 2.8  0.9 mmol/l, respectively;
oth p  0.3). The current therapy included methotrexate
n  13), other disease-modifying drug (n  7), nonsteroidal
nti-inflammatory drug (n  14), and prednisolone (n  9)
mean dose 6.7  3.2 mg). Most patients were taking 2 or
ore drugs concomitantly (n  18), and none were free from
edication. None of the patients were receiving medication for
ypertension or hypercholesterolemia. Patients remained on
heir existing therapy, and they did not receive corticosteroid
njections throughout the study period.
Table 2 shows the effect of ezetimibe and simvastatin on
ipids, inflammatory markers, disease activity, and hemody-
amic parameters after 6 weeks of each drug therapy; the
resented p values in the “Between Drugs” column are
onferroni adjusted. Both ezetimibe and simvastatin pro-
uced a significant reduction in total cholesterol, LDL
holesterol, and oxLDL. The reduction was more pro-
ounced with simvastatin than with ezetimibe. Baseline
xLDL was significantly higher in patients with RA com-
ared with control subjects (62.8 16.6 U/l vs. 43.6 12.9
/l, respectively; p  0.001). The ESR and CRP were
Placebo simvastatin / simvastatin / Washout
ezetimibe ezetimibe
0 2 8 Weeks14 20
Figure 1 The Study Design
Following 2-week placebo run-in, patients received simvastatin or ezetimibe in
a randomized double-blinded manner, each for 6 weeks, with a 6-week wash-
out between the drugs.educed by both ezetimibe and simvastatin. There were no
M
tignificant differences in the reduction in inflammatory
arkers between the 2 treatments.
Disease activity, assessed by DAS-28, fell by a similar
egree following both ezetimibe and simvastatin, and there
as no significant difference between the treatments. When
ooking at the individual components of DAS-28, the only
arameters that reached statistical significance were ESR
nd tender joints count. Neither mean arterial pressure nor
Ix was significantly affected by either drug. However,
ortic PWV was significantly reduced (Fig. 2) and FMD
ncreased (Fig. 3) following both drugs, and there was no
hange in the GTN response. (The p values in Figures 2 and
are Bonferroni adjusted.) There were no significant differ-
nces in the hemodynamic effects of the 2 treatments.
Custom hypothesis testing for the effect of treatment
rder showed that the order in which the drugs were
eceived did not affect any of the outcomes (p  0.05) and
here was no carryover effect of the previous treatment after
he 6-week washout period (unpaired t test between 2
aselines: p  0.05). In pooled data of both treatments, a
eduction in total, LDL, and oxLDL cholesterol were found
o correlate with the improvement of FMD (r  0.5,
0.5, and0.6, respectively; all p 0.05). We did not find
correlation between cholesterol reduction and improve-
ent of inflammatory markers or disease activity. There was
significant correlation between baseline CRP and change
n CRP (r  0.8; p  0.001) and between baseline ESR
aseline Demographics, Biochemical, andemodynamic Ch racteristics of Subjects Withheumatoid Arthritis (n  20)
Table 1
Baseline Demographics, Biochemical, and
Hemodynamic Characteristics of Subjects With
Rheumatoid Arthritis (n  20)
Age, yrs 58 12
Disease duration, yrs 13 10
Female, n (%) 16 (80%)
BMI, kg/m2 26.4 4.6
TC, mmol/l 5.3 0.9
TG, mmol/l 1.3 0.5
LDL cholesterol, mmol/l 3.1 0.9
HDL cholesterol, mmol/l 1.6 0.6
Glucose, mmol/l 4.8 0.5
Rheumatoid factor positive, n (%) 14 (70%)
CRP, mg/l 8.97 0.56*
ESR, mm/h 16 1*
DAS-28 4.65 1.44
SBP, mm Hg 137 17
DBP, mm Hg 84 11
MAP, mm Hg 102 12
Heart rate, beats/min 75 12
AP, mm Hg 13 7
AIx, % 29 10
aPWV, m/s 9.43 2.42
alues represent mean standard deviation, unless otherwise indicated. *Data are geometric
ean standard deviation, calculated from log-transformed distribution.
AIx  augmentation index; AP  augmentation pressure; aPWV  aortic pulse wave velocity;
RP  C-reactive protein; DAS Disease Activity Score; DBP  diastolic blood pressure; ESR 
rythrocyte sedimentation rate; HDL  high-density lipoprotein; LDL  low-density lipoprotein;
AP  mean arterial pressure; SBP  systolic blood pressure; TC  total cholesterol; TG 
riglycerides.
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WV occurring in subjects with the highest baseline ESR
Fig. 4).
The baseline aortic PWV was significantly increased in
atients with RA compared with control subjects (9.42 
.42 m/s vs. 7.69  1.18 m/s, respectively; p  0.005) and
ffect of Treatment on Lipids, Inflammation, Disease Activity, and
Table 2 Effect of Treatment on Lipids, Inflammation, Disease A
Baseline Ezetimibe
TC, mmol/l 5.3 1.0 4.7 1.0§
TG, mmol/l 1.5 0.7 1.3 0.7†
LDL, mmol/l 3.08 0.92 2.53 0.94§
HDL, mmol/l 1.59 0.55 1.65 0.57
TC/HDL ratio 3.67 1.44 3.11 1.51‡
oxLDL, U/l 61.4 16.6 55.7 18.4†
ESR, mm/h* 18.2 15.6 12.9 9.6†
CRP, mg/l* 14.2 14.7 8.8 9.4‡
DAS-28 4.41 1.20 3.86 1.57†
TJC 8.45 6.28 7.30 7.37
SJC 5.50 4.44 4.30 6.44
VAS 33.85 20.61 33.80 21.32
SBP, mm Hg 135 19 134 20
DBP, mm Hg 79 9 80 9
MAP, mm Hg 97 10 99 11
AP, mm Hg 15 9 14 7
AIX, % 27 11 26 10
aPWV, m/s 9.54 2.52 8.85 2.12†
Baseline diameter, mm 4.13 0.93 4.18 0.74
FMD, % 3.65 2.60 5.01 3.46†
GTN, % 8.39 3.37 8.49 3.40
alues represent mean standard deviation. Significance was determined using 2-way repeated m
ariables. †p 0.025; ‡p 0.01; §p 0.001; custom hypothesis testing of within-subject contrast
reatments was determined in post hoc tests with Bonferroni adjustment for 2 comparisons, whe
FMD  flow-mediated dilation; GTN  glyceryl trinitrate; oxLDL  oxidized low-density lipoprote
s in Table 1.
7.5
8.0
8.5
9.0
9.5
10.0
10.5
Baseline Ezetimibe Baseline Simvastatin
A
o
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 P
W
V
(m
/s
)
P=0.01 P<0.001
NS
Figure 2 Effect of 10 mg Ezetimibe
and 20 mg Simvastatin on Aortic PWV
Measurements were taken after 6 weeks of each treatment. Bars show mean
and standard error of mean (n  20). The omnibus significance for the trend
was p  0.001. The significance was determined by 2-way repeated measures
analysis of variance with post hoc testing with Bonferroni adjustment. PWV 
pulse wave velocity.MD was reduced (3.70  2.32% vs. 6.74  3.78%,
espectively; p  0.01). Following ezetimibe and simvasta-
in, FMD improved to a level similar to the control subjects
p  0.2 and p  0.8, respectively), but aortic PWV
emained elevated (p  0.02). There was no significant
hange in AIx following either drug.
dynamics After 6 Weeks of Treatment
y, and Hemodynamics After 6 Weeks of Treatment
Significance
aseline Simvastatin Overall Between Drugs
.4 0.9 4.1 0.7§ 0.001 0.001
.4 0.5 1.3 0.8 0.02 0.8
8 0.78 1.95 0.56§ 0.001 0.001
2 0.51 1.65 0.43 0.4 0.7
3 1.44 2.64 0.78§ 0.001 0.1
.0 17.5 43.3 14.1§ 0.001 0.003
.6 12.4 13.8 8.9† 0.006 0.9
.3 15.2 10.3 10.4§ 0.002 0.9
5 1.35 3.98 1.31‡ 0.002 0.7
0 8.33 7.40 7.27† 0.03 0.3
5 5.37 4.65 6.00 0.4 0.8
5 22.55 36.85 21.10 0.8 0.8
6 19 135 18 0.4 0.8
2 9 81 10 0.9 0.1
0 11 98 11 0.6 0.1
5 8 15 8 0.3 0.3
8 11 27 10 0.3 0.9
9 2.30 8.88 2.06§ 0.001 0.9
4 0.88 4.05 0.93 0.7 0.7
8 2.48 6.40 3.78‡ 0.001 0.1
3 2.70 8.10 3.41 0.9 0.9
s analysis of variance (ANOVA). *Log-transformed values were used for the analyses of the skewed
erformed for the comparison of ezetimibe versus simvastatin (final column): the effect of individual
ll significance in ANOVA was p  0.05.
 swollen joints count; TJC  tender joints count; VAS  visual analog score; other abbreviations
0
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Figure 3 Effect of 10 mg Ezetimibe
and 20 mg Simvastatin on FMD
Measurements were taken after 6 weeks of each treatment. Bars show mean
and standard error of mean (n  20). The omnibus significance for the trend
was p  0.001. The significance was determined by 2-way repeated measures
analysis of variance with post hoc testing with Bonferroni adjustment. FMD 
flow-mediated dilation.Hemo
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n the present study, we demonstrated that short-term
herapy with both ezetimibe and simvastatin significantly
educes cholesterol, inflammatory markers, and disease ac-
ivity in patients with active RA. Interestingly, despite a
ignificantly greater reduction in cholesterol following treat-
ent with simvastatin, the anti-inflammatory effects of the
wo drugs were similar. Moreover, we have shown for the
rst time, in a single cohort of RA patients, that both
zetimibe and simvastatin reduce aortic PWV and improve
ndothelial function.
The recent TARA study showed that statins reduce
nflammation and disease activity in patients with RA (15).
owever, it is unclear to what extent this effect is due to
holesterol reduction or true pleiotropism, because there
as no control cholesterol-lowering therapy. It is also
nclear whether treatment is associated with any improve-
ent in surrogate measures of cardiovascular risk. There-
ore, in the present study we assessed the effect of simva-
tatin as well as of the nonstatin cholesterol-lowering agent
zetimibe on inflammation, disease activity, and surrogate
easures of cardiovascular risk, such as endothelial function
nd aortic PWV, in a cohort of subjects with active RA.
nti-inflammatory effects. Treatment with ezetimibe and
imvastatin produced similar reductions in inflammatory
arkers and disease activity. The improvement of DAS-28
as mostly due to the reduction of ESR, but there was also
significant reduction in tender joints count. Although, the
eduction in inflammatory markers correlated with the
egree of baseline inflammation, there was no correlation
etween the extent of cholesterol reduction and fall in CRP
r DAS-28, which was also the case in the TARA study
15). This suggests either a potential “threshold effect” or
hat the reduction in cholesterol induced by ezetimibe and
imvastatin was not sufficiently different, or indeed large, to
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
0 10 20 30 40 50 60 70
Baseline ESR (mm/h)
C
ha
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m
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Figure 4 Relationship Between Baseline ESR and Change
in Aortic PWV Following Ezetimibe and Simvastatin
The change in aortic pulse wave velocity (PWV) following drug treatment was signif-
icantly associated with the baseline erythrocyte sedimentation rate (ESR); r 
0.416; p  0.008. Solid circles  ezetimibe; open circles  simvastatin.nmask such a relationship. rTreatment with statins has been consistently associated
ith a decrease in inflammatory markers (14,19,20) in a
ariety of patient groups, including subjects with RA (15).
owever, previous data suggest that ezetimibe only reduces
RP when given in combination with other agents (19,20).
ndeed, the present study is the first to show an anti-
nflammatory effect of ezetimibe per se. This may relate to
he relatively high level of systemic inflammation associated
ith RA patients compared with subjects with pure hyper-
holesterolemia or cardiovascular disease included in earlier
tudies (19,20). The present data are also the first to show
hat ezetimibe produces a clinical reduction of inflammation
nd disease activity in subjects with RA. It is unlikely that
ny such effects of ezetimibe are pleiotropic, because it is not
bsorbed into the circulation but acts locally by inhibiting
holesterol absorption from the small intestine. Taken
ogether, these observations suggest that cholesterol reduc-
ion per se has anti-inflammatory effects in patients with
A. This notion is supported by previous observations that
brates (21) and systemic Acyl-CoA cholesterol acyltrans-
erase (ACAT) inhibition (22) reduce inflammatory mark-
rs in other patient groups.
eduction of oxLDL. The anti-inflammatory effects seen
n the present study may be mediated by the reduction in
xLDL. Indeed, oxLDL is known to increase the expres-
ion of proinflammatory genes, leading to monocyte adhe-
ion to arterial endothelial cells (23,24). Moreover, recent
vidence from cultured human coronary artery endothelial
ells indicates that oxLDL, through its receptor LOX-1,
ctivates an inflammatory reaction by up-regulating CD40
nd CD40L signaling pathways, and CD40 antibody re-
uces oxLDL-induced tumor necrosis factor (TNF)-alpha
roduction (25). This may be especially important in RA,
hich is associated with elevated TNF-alpha signaling and
ncreased oxidative stress driven by high inflammation (26).
his could initiate a vicious circle, where inflammation-
riven oxidation of LDL leads to further increases in
nflammation, worsening of disease activity, and yet further
xidation, ultimately leading to endothelial dysfunction and
ardiovascular disease. The present results support this
heory by demonstrating that despite having LDL levels
imilar to control subjects, RA patients had higher oxLDL
evels and worse endothelial function at baseline.
eduction of arterial stiffness. We confirmed our original
bservations of increased aortic PWV in RA and for the first
ime demonstrated a significant reduction in aortic PWV
ith antihyperlipidemic drugs in patients with RA. The
eduction in aortic PWV correlated with the baseline ESR,
ith greatest reductions in PWV occurring in subjects with
he highest ESR. This finding is in line with other studies,
here greater clinical benefits of statins have been demon-
trated in patients with high levels of inflammation (27,28).
hese data also extend our previous observations that
nti–TNF-alpha therapy improves endothelial function and
educes aortic stiffness in RA (9) and suggest that even
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August 28, 2007:852–8 Cholesterol Reduction and Aortic Stiffness in RAodest reductions in systemic inflammation may lead to
eneficial effects on surrogates of cardiovascular risk.
We did not find any significant change in AIx following
ither drug. This suggests that despite reduction in wave
peed, there was no reduction in the impact of wave
eflection. This could be due to a fall in inflammation and
ubsequent peripheral vasoconstriction, which would lead to
ncreased impedance mismatch at the point of reflection,
nd therefore the net effect on AIx would remain un-
hanged. Our data contradict those of Efrati et al. (29), who
emonstrated that 40 mg simvastatin, but not 80 mg
imvastatin, 10 mg ezetimibe, or combination of 40 mg
imvastatin and 10 mg ezetimibe, reduces AIx. However,
hose data were based on small parallel groups (n  10).
mprovement of endothelial function. Statins improve
ndothelial function in patients with hypercholesterolemia
30), heart failure (31), coronary artery disease (CAD) (32),
nd RA (33). Most authors have ascribed this to the
leiotropic effect of statins, but, with the exception of 3
tudies (29,31,32), investigators have not controlled for the
holesterol reduction. In the present study, we demon-
trated for the first time that both ezetimibe and simvastatin
ignificantly improve endothelial function in RA to a level
imilar to healthy control subjects. Although the improve-
ent in FMD following simvastatin appeared greater than
hat following ezetimibe, it did not reach statistical signif-
cance. However, we cannot rule out the possibility that we
ould have reached a statistical significance if a larger
umber of patients were studied. Importantly, there was no
hange in the GTN response or baseline diameter of the
rachial artery between visits, suggesting that smooth mus-
le susceptibility to nitric oxide (NO) was not altered. The
eduction of total, LDL, and oxLDL cholesterol signifi-
antly correlated with the improvement of FMD, suggest-
ng that cholesterol, and especially oxLDL, reduction per se
mproves endothelial function. Our findings contradict
hose of Landmesser et al. (31) and Fichtlscherer et al. (32),
ho showed that only simvastatin and not ezetimibe im-
roved endothelial function. However, those studies were
erformed in patients with heart failure and CAD, not RA,
hich may explain the different findings. Moreover, al-
hough anti-TNF therapy has been associated with im-
roved cardiovascular outcome in patients with RA (34), it
orsens outcome in heart failure (35). Furthermore, the
tudy by Landmesser et al. (31) included only 20 patients in
parallel group design, whereas ours employed the same
umber of subjects in a crossover design, providing greater
ower.
ossible mechanisms behind the improvement of endo-
helial function. Support for the notion that cholesterol
eduction per se may improve endothelial vasomotor func-
ion comes from in vivo and in vitro observations. A number
f nonstatin therapies, such as a single LDL apheresis (36),
brates (21,37), and systemic ACAT inhibition (22) have
lready been linked with improved endothelial function in
ypercholesterolemic patients. Moreover, in vitro LDL
Etself inhibits endothelium-dependent vasodilatation (38).
he composition of lipid rafts within the plasma membrane
s also dependent on the circulating lipid profile. Indeed, the
xpression of scaffolding protein caveolin is increased in
ypercholesterolemia (39). Caveolin functions as an inhib-
tor of endothelial nitric oxide synthase (eNOS) by blocking
ccess of eNOS to its cofactor and substrate, thus reducing
O production (40) and possibly leading to endothelial
ysfunction. Therefore, lipid reduction may lead to de-
reased expression of caveolin and to restoration of normal
ransport of substrate L-arginine for eNOS (41).
tudy limitations. This study was powered to detect a
hange in CRP and DAS-28 with statin therapy, and our
ower calculations were based on the reductions seen in the
ARA study, but it was not powered to detect a difference
f 50% between the 2 treatments. The crossover design of
he study is an obvious strength, but also a weakness owing
o a potential carryover effect. Nevertheless, we did not find
carryover effect after a 6-week washout period, and the
rder of the drugs did not affect the outcome. We did not
ave a combined simvastatin and ezetimibe treatment pe-
iod and therefore we cannot answer whether this would
ave added to the effect we observed.
Furthermore, as with all chronic diseases, the disease
ctivity can fluctuate markedly during the course of a study,
specially if the duration is long. Therefore, our treatment
eriod was relatively short.
onclusions
e have shown that both ezetimibe and simvastatin reduce
nflammatory markers ESR and CRP as well as disease
ctivity to a similar degree in patients with RA. We have
lso shown, for the first time in a randomized double-blind
tudy, that endothelial function and concomitantly arterial
tiffness were improved by both drugs. These results suggest
hat the reduction of cholesterol per se ameliorates aortic
tiffness and endothelial dysfunction. Our data also suggest
hat cholesterol-reducing therapies may be beneficial for RA
atients, because they are well tolerated, improve clinical
utcome. and reduce surrogates of cardiovascular risk. Fu-
ure studies are needed to establish whether a reduction of
rterial stiffness and improvement of endothelial function
ith antihyperlipidemic agents translates to an improve-
ent in cardiovascular outcome in patients with RA.
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